Cosmo to acquire BioXell

Specialty pharmaceutical company Cosmo Pharmaceuticals S.p.A. (SIX:COPN) will acquire BioXell S.p.A. (SIX:BXLN) in a cash, stock and put option transaction that the companies said values BioXell at CHF7.68 per share, or CHF41.3 million ($41 million), based on 5.4 million shares outstanding on Tuesday. The price, which includes CHF2.81 per share in cash, is a 24% premium to BioXell's Tuesday close of CHF6.20. ...